289 related articles for article (PubMed ID: 32154367)
1. Ocular side effects of antirheumatic medications: a qualitative review.
M Castillejo Becerra C; Ding Y; Kenol B; Hendershot A; Meara AS
BMJ Open Ophthalmol; 2020; 5(1):e000331. PubMed ID: 32154367
[TBL] [Abstract][Full Text] [Related]
2. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
Hadjinicolaou AV; Nisar MK; Bhagat S; Parfrey H; Chilvers ER; Ostör AJ
Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
[TBL] [Abstract][Full Text] [Related]
3. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
4. Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review.
Dammacco R; Guerriero S; Alessio G; Dammacco F
Int Ophthalmol; 2022 Feb; 42(2):689-711. PubMed ID: 34802085
[TBL] [Abstract][Full Text] [Related]
5. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents.
Infante M; Padilla N; Alejandro R; Caprio M; Della-Morte D; Fabbri A; Ricordi C
Medicina (Kaunas); 2022 Apr; 58(5):. PubMed ID: 35629988
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.
Lalor AF; Brooker JE; Rozbroj T; Whittle SL; Hill CL; Rowett D; Buchbinder R; O'Connor DA
Semin Arthritis Rheum; 2022 Aug; 55():151988. PubMed ID: 35286905
[TBL] [Abstract][Full Text] [Related]
8. [Conventional Synthetic Disease-modifying Antirheumatic Drugs (DMARDs) for the Treatment of Non-infectious Uveitis].
Tappeiner C; Rath T; Heiligenhaus A
Klin Monbl Augenheilkd; 2018 May; 235(5):562-567. PubMed ID: 29739025
[TBL] [Abstract][Full Text] [Related]
9. Antirheumatic drugs in older adults and polypharmacy issues.
Coskun Benlidayi I; Gokce Kutsal Y
Z Gerontol Geriatr; 2022 Oct; 55(6):507-512. PubMed ID: 34114088
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review.
Hsieh TS; Tsai TF
Dermatol Ther (Heidelb); 2023 Apr; 13(4):891-909. PubMed ID: 36943580
[TBL] [Abstract][Full Text] [Related]
11. Rheumatological Adverse Events Following Immunotherapy for Cancer.
Cretu I; Cretu B; Cirstoiu C; Cursaru A; Milicescu M; Bojinca M; Ionescu R
Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056402
[No Abstract] [Full Text] [Related]
12. The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.
Ding Q; Shiltz D; Hossami D; Konieczny AM
Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1231-1241. PubMed ID: 36004551
[TBL] [Abstract][Full Text] [Related]
13. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
14. Ophthalmic complications of immune checkpoint inhibitors.
Wladis EJ; Kambam ML
Orbit; 2022 Feb; 41(1):28-33. PubMed ID: 33386059
[TBL] [Abstract][Full Text] [Related]
15. Comparison of conventional immunosuppressive drugs versus anti-TNF-α agents in non-infectious non-anterior uveitis.
Leclercq M; Langlois V; Girszyn N; Le Besnerais M; Benhamou Y; Levesque H; Muraine M; Gueudry J
J Autoimmun; 2020 Sep; 113():102481. PubMed ID: 32586650
[TBL] [Abstract][Full Text] [Related]
16. [Uveitis treated with biotherapy and/or DMARD: Analysis from the French Pharmacovigilance Study Base].
Cabane L; Baillif S; Baldin B; Breuil V; Euller-Ziegler L; Tieulié N
J Fr Ophtalmol; 2018 Apr; 41(4):350-356. PubMed ID: 29656829
[TBL] [Abstract][Full Text] [Related]
17. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
[TBL] [Abstract][Full Text] [Related]
18. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
[TBL] [Abstract][Full Text] [Related]
19. Laboratory screening for side effects of disease modifying antirheumatic drugs in daily rheumatological practice.
Simon CH; Vliet Vlieland TP; Dijkmans BA; Bernelot Moens HJ; Janssen M; Hazes JM; Franken HC; Vandenbroucke JP; Breedveld FC
Scand J Rheumatol; 1998; 27(3):170-9. PubMed ID: 9645411
[TBL] [Abstract][Full Text] [Related]
20. [Clinical aspects, diagnostics and differential diagnostics of uveitis for rheumatologists].
Stübiger N; Farrokhi S; Gkanatsas Y; Deuter C; Kötter I
Z Rheumatol; 2022 Sep; 81(7):587-595. PubMed ID: 36018374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
